Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Madrigal Pharmaceuticals Inc banner

Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 530.05 USD -3.04% Market Closed
Market Cap: $12.2B
Write Note Create Alert Ask AI

Wall St Price Targets

MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc

Wall Street analysts forecast MDGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDGL is 691.74 USD with a low forecast of 548.43 USD and a high forecast of 1 010.1 USD.

MDGL Lowest Forecast
Wall Street Target
$548.43
3% Upside
MDGL Average Forecast
Wall Street Target
$691.74
31% Upside
MDGL Highest Forecast
Wall Street Target
$1 010.1
91% Upside
Lowest Forecast
Price Target
548.43 USD
3% Upside
Average Forecast
Price Target
691.74 USD
31% Upside
Highest Forecast
Price Target
1 010.1 USD
91% Upside
Madrigal Pharmaceuticals Inc Competitors:
Price Targets
LAND
Gladstone Land Corp
6% Upside
QNST
Quinstreet Inc
27% Upside
IDXX
IDEXX Laboratories Inc
41% Upside
VAC
Pierre et Vacances SA
16% Upside
LAND
Gladstone Land Corp
6% Upside
QNST
Quinstreet Inc
27% Upside
IDXX
IDEXX Laboratories Inc
41% Upside
VAC
Pierre et Vacances SA
16% Upside

Revenue
Forecast

102% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
102% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 102%. The projected CAGR for the next 8 years is 27%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
26% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
26% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Gross Profit over the next 8 years is 26%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Continue MDGL Research

Summary
MDGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
MDGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MDGL stock valuation using valuation multiples.
Wall St Estimates
MDGL price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MDGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Madrigal Pharmaceuticals Inc listings:
LSE • USD
0JXI
 F • EUR
YDO1
 SWB • EUR
YDO1
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MDGL's stock price target?
Price Target
691.74 USD

According to Wall Street analysts, the average 1-year price target for MDGL is 691.74 USD with a low forecast of 548.43 USD and a high forecast of 1 010.1 USD.

What is the Revenue forecast for Madrigal Pharmaceuticals Inc?
Projected CAGR
27%

Over the last 13 years, the compound annual growth rate for Revenue has been 102%. The projected CAGR for the next 8 years is 27%.

What is the Gross Profit forecast for Madrigal Pharmaceuticals Inc?
Projected CAGR
26%

The compound annual growth rate for Gross Profit over the next 8 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett